Below are the most recent publications written about "Astrocytoma" by people in Profiles.
-
Ninatti G, Sollini M, Bono B, Gozzi N, Fedorov D, Antunovic L, Gelardi F, Navarria P, Politi LS, Pessina F, Chiti A. Preoperative [11C]methionine PET to personalize treatment decisions in patients with lower-grade gliomas. Neuro Oncol. 2022 09 01; 24(9):1546-1556.
-
Abd-El-Barr MM, Huang KT, Moses ZB, Iorgulescu JB, Chi JH. Recent advances in intradural spinal tumors. Neuro Oncol. 2018 05 18; 20(6):729-742.
-
Pricola Fehnel K, Duggins-Warf M, Zurakowski D, McKee-Proctor M, Majumder R, Raber M, Han X, Smith ER. Using urinary bFGF and TIMP3 levels to predict the presence of juvenile pilocytic astrocytoma and establish a distinct biomarker signature. J Neurosurg Pediatr. 2016 Oct; 18(4):396-407.
-
Cachia D, Prado MP, Theeler B, Hamilton J, McCutcheon I, Fuller GN. Synchronous rosette-forming glioneuronal tumor and diffuse astrocytoma with molecular characterization: a case report. Clin Neuropathol. 2014 Nov-Dec; 33(6):407-11.
-
?rias U, Marie SK, Uno M, da Silva R, Evagelinellis MM, Caballero OL, Stevenson BJ, Silva WA, Simpson AJ, Oba-Shinjo SM. CD99 is upregulated in placenta and astrocytomas with a differential subcellular distribution according to the malignancy stage. J Neurooncol. 2014 Aug; 119(1):59-70.
-
Dreyfuss JM, Johnson MD, Park PJ. Meta-analysis of glioblastoma multiforme versus anaplastic astrocytoma identifies robust gene markers. Mol Cancer. 2009 Sep 04; 8:71.
-
Mohile NA, Forsyth P, Stewart D, Raizer JJ, Paleologos N, Kewalramani T, Louis DN, Cairncross JG, Abrey LE. A phase II study of intensified chemotherapy alone as initial treatment for newly diagnosed anaplastic oligodendroglioma: an interim analysis. J Neurooncol. 2008 Sep; 89(2):187-93.
-
Polin RS, Marko NF, Ammerman MD, Shaffrey ME, Huang W, Anderson FA, Caputy AJ, Laws ER. Functional outcomes and survival in patients with high-grade gliomas in dominant and nondominant hemispheres. J Neurosurg. 2005 Feb; 102(2):276-83.
-
Simin K, Hill R, Song Y, Zhang Q, Bash R, Cardiff RD, Yin C, Xiao A, McCarthy K, van Dyke T. Deciphering cancer complexities in genetically engineered mice. Cold Spring Harb Symp Quant Biol. 2005; 70:283-90.
-
Sampath P, Weaver CE, Sungarian A, Cortez S, Alderson L, Stopa EG. Cerebrospinal fluid (vascular endothelial growth factor) and serologic (recoverin) tumor markers for malignant glioma. Cancer Control. 2004 May-Jun; 11(3):174-80.